Анализа корелације нивоа серума NT-прo-BNP, IGFBP-7 и CTRP12 код пацијената са хроничном срчаном инсуфицијенцијом
Нивои серума NT-прo-BNP, ИГФБП-7 и ЦТРП12 код хроничне срчане инсуфицијенције
Sažetak
Objective: To investigate serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP), insulin-like growth factor binding protein-7 (IGFBP-7), and C1q tumor necrosis factor-related protein 12 (CTRP12) levels and significance in patients with chronic heart failure (CHF).
Methods: The CHF group consisted of 116 CHF patients who received care at this hospital between October 2023 and March 2025. The patients were classified into Grade II (47 patients), Grade III (41 patients), or Grade IV (28 patients) based on the heart function classification of the New York Heart Association (NYHA). The control group consisted of 64 healthy patients who were examined physically in the hospital throughout the same time period. Using multivariate logistic regression, the factors impacting MACEs in patients with congestive heart failure were examined. Through the use of the receiver operating characteristic (ROC) curve, researchers were able to assess the predictive power of blood NT-pro-BNP, IGFBP-7, and CTRP12 for MACEs in chronic heart failure patients.
Results: Comparing the CHF group to the control group, the LVEDD increased, the LVEF and serum CTRP12 decreased, and the levels of NT-pro-BNP, IGFBP-7, Hcy, and hs-CRP climbed (P<0.05). Among patients with CHF of different grades, serum NT-pro-BNP, IGFBP-7, Hcy, hs-CRP, and LVEDD levels were all lower in Grade II patients than in Grade III patients. Furthermore, the differences between any two grades were statistically significant (P<0.05). The levels of LVEF and serum CTRP12 in the MACE group decreased, the LVEDD increased, and the levels of serum Hcy, hs-CRP, NT-pro-BNP and IGFBP-7 increased (P<0.05). MACEs in CHF patients were influenced by serum NT-pro-BNP, IGFBP-7, and CTRP12 (P<0.05). The areas under the curve (AUCs) of serum NT-pro-BNP, IGFBP-7, CTRP12 alone and the combination of the three for predicting MACEs in patients with CHF were 0.862 (95% CI: 0.786–0.919), 0.805 (95% CI: 0.721–0.872), and 0.860 (95% CI: 0.784–0.918) and 0.961 (95% CI: 0.908–0.988), respectively. The AUCs of the three combined predictions were significantly greater than those of the individual predictions of NT-pro-BNP, IGFBP-7, and CTRP12 (Z=3.050, 3.883, 3.218, all P<0.05).
Conclusion: Serum levels of IGFBP-7 and NT-pro-BNP increase in CHF patients, whereas the level of CTRP12 decreases. Additionally, once functional classification was applied, NT-pro-BNP, IGFBP-7, and CTRP12 levels changed. The combined detection of these three parameters has better efficacy in predicting MACEs in patients with CHF.
Reference
2.Hendricks S, Dykun I, Balcer B, Totzeck M, Rassaf T, Mahabadi AA. Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. ESC Heart Fail. 2022 Oct;9(5):3198-3209. doi: 10.1002/ehf2.14019. Epub 2022 Jun 29. PMID: 35769032; PMCID: PMC9715818.
3.Mei B, Yuan L, Shu Y. Quantitative Evidence of the effect of Baduanjin exercise on quality of life and cardiac function in adults with chronic heart failure. Complement Ther Clin Pract. 2023 Nov;53:101775. doi: 10.1016/j.ctcp.2023.101775. Epub 2023 Jun 11. PMID: 37717550.
4.Militaru M, Lighezan DF, Tudoran C, Tudoran M, Militaru AG. Factors Influencing the Development and Severity of Cognitive Decline in Patients with Chronic Heart Failure. Medicina (Kaunas). 2024 Nov 13;60(11):1859. doi: 10.3390/medicina60111859. PMID: 39597044; PMCID: PMC11596752.
5.Moscucci F, Sciomer S, Maffei S, Meloni A, Lospinuso I, Carnovale M, Corrao A, Di Diego I, Caltabiano C, Mezzadri M, Mattioli AV, Gallina S, Rossi P, Magrì D, Piccirillo G. Sex Differences in Repolarization Markers: Telemonitoring for Chronic Heart Failure Patients. J Clin Med. 2023 Jul 16;12(14):4714. doi: 10.3390/jcm12144714. PMID: 37510828; PMCID: PMC10381165.
6.Dattilo G, Bitto R, Correale M, Morabito C, Vaccaro V, Laterra G, Casale M, Crea P, DI Bella G, Luzza F, Migliorato A, Katsiki N, DE Gregorio C. Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience. Minerva Cardiol Angiol. 2022 Oct;70(5):555-562. doi: 10.23736/S2724-5683.20.05494-8. Epub 2021 Apr 7. PMID: 33823573.
7.Chen W, Luo X, Li W, Li X, Wang Y, Zhang R, Liu B, Zhu L, Liu Z, Cheng Y. Uncovering the active ingredients of Xinbao pill against chronic heart failure: A chemical profiling, pharmacokinetics and pharmacodynamics integrated study. J Ethnopharmacol. 2025 Feb 27;342:119418. doi: 10.1016/j.jep.2025.119418. Epub 2025 Jan 27. PMID: 39880064.
8.Naser N, Kulić M, Jatić Z. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting. Med Arch. 2022 Apr;76(2):101-107. doi: 10.5455/medarh.2022.76.101-107. PMID: 35774049; PMCID: PMC9233466.
9.Sharma S, Mathur D, Goswami S, Gupta MK, Bhardwaj P, Kumar P, Deora S. Prevalence of periodontitis in chronic heart failure patients and its relationship with NT-ProBNP: A cross-sectional study. Indian Heart J. 2025 Mar-Apr;77(2):110-113. doi: 10.1016/j.ihj.2025.03.004. Epub 2025 Mar 7. PMID: 40057232; PMCID: PMC12138112.
10.Feng ZF, Liu Y, Salvador JT, Ala MB, Nery MAC, Huang XY, Zhang L, Liu S. Implementation and evaluation of hospital-to-home transitional care intervention in patients with chronic heart failure. BMC Nurs. 2025 Jul 1;24(1):717. doi: 10.1186/s12912-025-03447-5. PMID: 40597265; PMCID: PMC12210740.
11.Pages N, Picard F, Barritault F, Amara W, Lafitte S, Maribas P, Abassade P, Labarre JP, Boulestreau R, Chaouky H, Abdennadher M, Lemieux H, Lasserre R, Bedel C, Betito L, Nisse-Durgeat S, Diebold B. Remote patient monitoring for chronic heart failure in France: When an innovative funding program (ETAPES) meets an innovative solution (Satelia® Cardio). Digit Health. 2022 Aug 22;8:20552076221116774. doi: 10.1177/20552076221116774. PMID: 36034602; PMCID: PMC9403459.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
13.Lin ZB, Teng ZH, Xu YR, Deng YS, Liang GL, Deng HY, Zeng QC. [Predictive value of whole blood cell derived inflammatory markers in combination with NT-proBNP on the prognosis of patients with chronic heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025 Feb 24;53(2):143-150. Chinese. doi: 10.3760/cma.j.cn112148-20241211-00774. PMID: 39965849.
14.Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Drożdż J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Lindholm D, Hammarstedt A, Boulton DW, Greasley PJ, Langkilde AM, Solomon SD, Sattar N, McMurray JJV, Jhund PS. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. JACC Heart Fail. 2023 Mar;11(3):291-304. doi: 10.1016/j.jchf.2022.09.004. Epub 2022 Nov 9. PMID: 36592046.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
16.Ferreira JP, Packer M, Sattar N, Butler J, González Maldonado S, Panova-Noeva M, Sumin M, Masson S, Pocock SJ, Anker SD, Zannad F, Januzzi JL. Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme. Eur J Heart Fail. 2024 Apr;26(4):806-816. doi: 10.1002/ejhf.3227. Epub 2024 Apr 8. PMID: 38587259.
17.Moltó-Balado P, Reverté-Villarroya S, Monclús-Arasa C, Balado-Albiol MT, Baset-Martínez S, Carot-Domenech J, Clua-Espuny JL. Heart Failure and Major Adverse Cardiovascular Events in Atrial Fibrillation Patients: A Retrospective Primary Care Cohort Study. Biomedicines. 2023 Jun 26;11(7):1825. doi: 10.3390/biomedicines11071825. PMID: 37509465; PMCID: PMC10376826.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
19.Du J, Yang L, Hao Z, Li H, Yang C, Wang X, Zhang Z, Du Y, Zhang Y. Development and validation of a nomogram for major adverse cardiovascular events after chronic total occlusion percutaneous coronary intervention for ischemic heart failure. Catheter Cardiovasc Interv. 2024 Sep;104(3):451-461. doi: 10.1002/ccd.31139. Epub 2024 Jul 20. PMID: 39033330.
20.Aggarwal R, Bhatt DL, Szarek M, Cannon CP, Leiter LA, Inzucchi SE, Lopes RD, McGuire DK, Lewis JB, Riddle MC, Davies MJ, Banks P, Carroll AK, Scirica BM, Ray KK, Kosiborod MN, Cherney DZI, Udell JA, Verma S, Mason RP, Pitt B, Steg PG. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomized trial. Lancet Diabetes Endocrinol. 2025 Apr;13(4):321-332. doi: 10.1016/S2213-8587(24)00362-0. Epub 2025 Feb 14. PMID: 39961315.
21.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
22.Kavousi S, Hosseinpour A, Bahmanzadegan Jahromi F, Attar A. Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart failure: a meta-analysis of randomized controlled trials. J Transl Med. 2024 Aug 22;22(1):786. doi: 10.1186/s12967-024-05352-y. PMID: 39174960; PMCID: PMC11342608.
23.Le Gall L, Harambat J, Combe C, Philipps V, Proust-Lima C, Dussartre M, Drüeke T, Choukroun G, Fouque D, Frimat L, Jacquelinet C, Laville M, Liabeuf S, Pecoits-Filho R, Massy ZA, Stengel B, Alencar de Pinho N, Leffondré K, Prezelin-Reydit M; CKD-REIN study group. Hemoglobin trajectories in chronic kidney disease and risk of major adverse cardiovascular events. Nephrol Dial Transplant. 2024 Mar 27;39(4):669-682. doi: 10.1093/ndt/gfad235. PMID: 37935529.
24.Desingu R, Kaore S, Kandelwal G, Balakrishnan S. Evaluation of ivabradine plus beta-blocker versus beta-blocker alone in addition to standard care in reducing hospitalization and major adverse cardiovascular event in patients with chronic heart failure: a prospective observational study in tertiary care hospital in central India. Egypt Heart J. 2024 May 31;76(1):67. doi: 10.1186/s43044-024-00500-7. PMID: 38819505; PMCID: PMC11143102.
25.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
26.Zhang L, Ou X, Lin J, Luo X, Zhou J, Zhou X, Zhao P, Liu L, Zhao Z, Zhou Y, Fan G, Han L, Gao X. Red Blood Cell Membrane Lipidomics: Potential Biomarkers Detecting Method for Plasma Volume Overload and Major Adverse Cardiovascular Events in Chronic Heart Failure Patients. Adv Sci (Weinh). 2025 Jun 23:e02893. doi: 10.1002/advs.202502893. Epub ahead of print. PMID: 40548468.
27.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
28.Farag SI, Mostafa SA, Kabil H, Elfaramawy MR. Chronic kidney disease's impact on revascularization and subsequent major adverse cardiovascular events in patients with chronic coronary syndrome. Indian Heart J. 2024 Jan-Feb;76(1):22-26. doi: 10.1016/j.ihj.2023.11.006. Epub 2023 Nov 23. PMID: 38000533; PMCID: PMC10943565.
29.Sulaiman S, Mohamed Khalafallah RA, Elbadri A, Abuelgasim Mohamedsalih TM, Mahmoud A, Mohamed Salih Abdelrahman MA, Hassan IM. Serum Galectin-3 and Risk Stratification in Chronic Heart Failure: A Systematic Review of Mortality Outcomes. Cureus. 2025 Jun 29;17(6):e86959. doi: 10.7759/cureus.86959. PMID: 40734851; PMCID: PMC12306356.
30.Traub J, Schuhmann MK, Sell R, Frantz S, Störk S, Stoll G, Frey A. S100B Serum Levels in Chronic Heart Failure Patients: A Multifaceted Biomarker Linking Cardiac and Cognitive Dysfunction. Int J Mol Sci. 2024 Aug 22;25(16):9094. doi: 10.3390/ijms25169094. PMID: 39201780; PMCID: PMC11354705.
31.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
32.Armentaro G, Condoleo V, Pastura CA, Grasso M, Frasca A, Martire D, Cassano V, Maio R, Bonfrate L, Pastori D, Montalcini T, Andreozzi F, Sesti G, Violi F, Sciacqua A. Prognostic role of serum albumin levels in patients with chronic heart failure. Intern Emerg Med. 2024 Aug;19(5):1323-1333. doi: 10.1007/s11739-024-03612-9. Epub 2024 May 22. PMID: 38776047; PMCID: PMC11364577.
33.Zheng YY, Wu TT, Hou XG, Yang HT, Yang Y, Xiu WJ, Pan Y, Ma YT, Mahemuti A, Xie X. Serum a-1 antitrypsin as a novel biomarker in chronic heart failure. ESC Heart Fail. 2023 Oct;10(5):2865-2874. doi: 10.1002/ehf2.14451. Epub 2023 Jul 7. PMID: 37417425; PMCID: PMC10567649.
34.Ni F, Xiang Y. Correlation between serum cystatin C and lipid level in patients with chronic heart failure. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Jan 28;48(1):34-39. English, Chinese. doi: 10.11817/j.issn.1672-7347.2023.220025. PMID: 36935175; PMCID: PMC10930551.
35.Xie L, Zhou Z, Chen HX, Yan XY, Ye JQ, Jiang Y, Zhou L, Zhang Q. Correlations between serum laminin level and severity of heart failure in patients with chronic heart failure. Front Cardiovasc Med. 2023 Mar 16;10:1089304. doi: 10.3389/fcvm.2023.1089304. PMID: 37008313; PMCID: PMC10060624.
36.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
37.Amaechi UM, Aiwuyo HO, Ewelukwa C, Ilerhunmwuwa N, Osarenkhoe JO, Kweki AG, Onuwaje OE, Mbakwem A, Kehinde M. Assessing Iron Status in Chronic Heart Failure Patients by Using Serum Ferritin and Transferrin Saturation Levels: A Cross-Sectional Descriptive Study. Cureus. 2023 May 24;15(5):e39425. doi: 10.7759/cureus.39425. PMID: 37362450; PMCID: PMC10288524.
38.Matin SS, Shidfar F, Naderi N, Amin A, Hosseini-Baharanchi FS, Dehnad A. The impact of synbiotic on serum sCD163/sTWEAK, paraoxonase 1, and lipoproteins in patients with chronic heart failure: a randomized, triple-blind, controlled trial. Sci Rep. 2024 Aug 18;14(1):19120. doi: 10.1038/s41598-024-69560-8. PMID: 39155305; PMCID: PMC11330970.
Sva prava zadržana (c) 2025 Zhen Fan, Heng Huang, Hejuan Hua, Lin Chen, Laoji Wang, Jierou Yan, Fei Zhao

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
